Positive Results Published in NEJM for Clinical Trial of Cannabis in Lennox-Gastaut Syndrome

BOHEMIA, N.Y. – May 17, 2018 – (Newswire.com)

The New England Journal of Medicine has published positive results from a clinical trial of Cannabidiol in Lennox-Gastaut Syndrome.

Cannabidiol (CBD), a compound derived from the cannabis plant that does not produce a “high” has been an increasing focus of medical research in epilepsy. New study results from the clinical trial of Epidiolex® has shown to significantly reduce the number of seizures in patients with Lennox-Gastaut Syndrome.

Lennox-Gastaut Syndrome is a rare and severe form of childhood-onset epilepsy that typically persists into adulthood. Despite currently available medications and a poly-therapy approach to treatment, most individuals with LGS will continue to have life-long, debilitating seizures.

The results of the study, which were published in the New England Journal of Medicine, compared two doses of CBD to placebo. Researchers reported a 41.9% reduction in “drop seizures” for those taking a 20mg/kg/d regimen and a 37.2% reduction

... read more at: http://www.digitaljournal.com/pr/3779771